Trial Profile
A Phase II Study of MK-0683 in Patients With Relapsed / Refractory Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 15 Feb 2019 Status changed from active, no longer recruiting to completed.
- 08 Feb 2018 Planned End Date changed from 31 Jan 2018 to 31 Jan 2019.
- 13 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.